PD-(L)1 Archives - Medical Conferences

Benefit of first-line nivolumab/ipilimumab in MSI-H/dMMR metastatic CRC

Presented By

Prof. Heinz-Josef Lenz, University of Southern California Norris Comprehensive Cancer Center, CA, USA

Trial

Phase 3, CheckMate 8HW

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 15:44

Neoadjuvant checkpoint blockade in MSI-H/dMMR CRC

Trial

Phase 1/2, NICHE-2, NEOPRISM-CRC

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 15:36

Nivolumab/ipilimumab combination outperforms TKIs in unresectable HCC

Presented By

Dr Peter Galle, Universitätsmedizin Mainz, Germany

Trial

Phase 3, CheckMate 9DW

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 15:10

Adjuvant avelumab significantly improves survival in early TNBC

Presented By

Prof. Pierfranco Conte, University of Padova, Italy

Trial

Phase 3, A-BRAVE

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:53

Highly significant event-free survival benefit with neoadjuvant nivolumab/ipilimumab in stage III melanoma

Presented By

Prof. Christian Blank, Antoni van Leeuwenhoek, the Netherlands

Trial

Phase 3, NADINA

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:16

Intratumoural tilsotolimod shows no benefit for advanced refractory melanoma

Presented By

Prof. Caroline Robert, Gustave Roussy, France

Trial

Phase 3, ILLUMINATE-301

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:09

Biomarkers for treatment of renal cell carcinoma

Trial

Phase 3, CLEAR, KEYNOTE-426, IMmotion010

Conference

ASCO 2024

Type

Peer-reviewed article

18 July 2024 14:00

Addition of atezolizumab to chemotherapy and maintenance PARP inhibitor has no benefit in ovarian cancer

Presented By

Prof. Antonio Gonzalez Martin, Cancer Centre Clinica Universidad de Navarre, Spain

Trial

Phase 3, ANITA

Conference

ESMO 2023

Type

Peer-reviewed article

19 December 2023 12:43

IMbrave 151 missed primary endpoint in advanced BTC

Presented By

Prof. Anthony El-Khoueiry, USC Norris Comprehensive Cancer Center, CA, USA

Trial

Phase 2, IMbrave151

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 09:15

Combination botensilimab plus balstilimab demonstrates promising activity in heavily pre-treated MSS CRC

Presented By

Prof. Anthony El-Khoueiry, Norris Comprehensive Cancer Center, CA, USA

Trial

Phase 1, C-800

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 09:06

Neoadjuvant immunotherapy is safe and efficacious in a phase 2 gastric cancer trial

Presented By

Dr Filippo Pietrantonio, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy

Trial

Phase 2, INFINITY

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 08:19

ZNF689 deficiency promotes intratumour heterogeneity and resistance to immune checkpoint blockade in TNBC

Presented By

Dr Li-Peng Ge, Fudan University Shanghai Cancer Center, China

Conference

SABCS 2022

Type

Peer-reviewed article

1 February 2023 18:17

Stimulation of PD-1: a new concept to treat RA

Presented By

Prof. Paul Emery, University of Leeds, UK

Trial

Phase 2

Conference

ACR 2022

Type

News article

1 December 2022 14:28

Sugemalimab offers PFS benefits for unresectable NSCLC

Presented By

Prof. Yi-Long Wu, Guangdong Provincial People’s Hospital, China

Trial

Phase 3, GEMSTONE-301

Conference

WCLC 2022

Type

News article

23 August 2022 11:10

IMpower010: First interim OS analysis of adjuvant atezolizumab in NSCLC

Presented By

Dr Enriqueta Felip, Vall d’Hebron University Hospital, Spain

Trial

Phase 3, IMpower010

Conference

WCLC 2022

Type

News article

23 August 2022 11:02

NADIM: Risk of progression identified through RNA sequencing

Presented By

Ms Marta Casarrubios, Hospital Universitario Puerta de Hierro-Majadahonda, Spain

Trial

Phase 2, NADIM

Conference

WCLC 2022

Type

News article

23 August 2022 10:55

NADIM II: OS benefit of neoadjuvant nivolumab plus chemotherapy in NSCLC

Presented By

Dr Mariano Provencio, Hospital Universitario Puerta de Hierro-Majadahonda, Spain

Trial

Phase 2, NADIM II

Conference

WCLC 2022

Type

News article

23 August 2022 10:52

POSEIDON: Novel option for harder-to-treat subgroups of patients with metastatic NSCLC?

Presented By

Prof. Solange Peters, Lausanne University, Switzerland

Trial

Phase 3, POSEIDON

Conference

WCLC 2022

Type

News article

23 August 2022 10:47

KEYNOTE-604: Very durable responses on pembrolizumab plus EP in SCLC

Presented By

Dr Charles Rudin, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 3, KEYNOTE-604

Conference

WCLC 2022

Type

News article

23 August 2022 10:41

Pembrolizumab plus lenvatinib performs well in MPM

Presented By

Dr Li-Anne Douma, Netherlands Cancer Institute - Antoni van Leeuwenhoek, the Netherlands

Trial

Phase 2, PEMMELA

Conference

WCLC 2022

Type

News article

23 August 2022 10:34

Spectacular results for dostarlimab in mismatch repair deficient rectal cancer

Presented By

Dr Andrea Cercek, Memorial Sloan Kettering Cancer Center, NY, USA

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 15:14

Exploratory treatment options fail in ccRCC

Presented By

Prof. Thomas Powles, University of London, UK

Trial

Phase 2, CALYPSO

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 14:18

Higher response rates for concurrent triple therapy versus sequential therapy in melanoma

Presented By

Prof. Georgina Long, The University of Sydney, Australia

Trial

Phase 2, NeoTrio

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 13:50

Success for serplulimab plus chemotherapy in small cell lung cancer

Presented By

Prof. Ying Cheng, Jilin Cancer Hospital, China

Trial

Phase 3, ASTRUM-005

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 12:38

Long-term benefits of combined immunotherapy over chemotherapy in non-small cell lung cancer

Presented By

Prof. Julie Brahmer, Sidney Kimmel Comprehensive Cancer Center, Australia

Trial

Phase 3, CheckMate 227

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 12:29

Effect of KRAS mutations and PD-L1 expression on therapy response in non-small cell lung cancer

Presented By

Dr Oladimeji Akinboro, US Food and Drug Administration, MD, USA

Conference

ASCO 2022

Type

Peer-reviewed article

5 August 2022 12:26

Abscopal response in patients with relapsed or refractory Hodgkin lymphoma who failed on anti-PD1 treatment

Presented By

Dr Paul Bröckelmann, University Hospital of Cologne, Germany

Trial

Phase 2, AERN

Conference

EHA 2022

Type

News article

1 July 2022 11:37

Sintilimab plus chemotherapy improves OS in treatment-naïve, stage III–IV non-squamous NSCLC

Presented By

Dr Yunpeng Yang, Sun Yat-sen University Cancer Center, China

Trial

Phase 3, ORIENT-11

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:39

Updated results of CameL-sq trial confirm benefit of camrelizumab

Presented By

Prof. Caicun Zhou, Shanghai Pulmonary Hospital, China

Trial

Phase 3, CameL-sq

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:38

No long-term benefit of adding ipilimumab to pembrolizumab in metastatic NSCLC

Presented By

Dr Delvys Rodriguez-Abreu, Universidad de Las Palmas de Gran Canaria, Spain

Trial

Phase 3, KEYNOTE-598

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:38

In concurrent CRT for stage III, unresectable NSCLC, performance status is better with proton therapy than photon therapy

Presented By

Dr Francesco Cortiula, Maastricht University Medical Center, the Netherlands

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:37

No improved prognosis for concurrent versus sequential immune checkpoint inhibition and CRT in unresectable NSCLC

Presented By

Dr Lukas Käsmann, University Hospital Munich, Germany

Trial

Phase 3

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:37

Durvalumab after sequential CRT safe in stage III, unresectable NSCLC

Presented By

Dr Marina Garassino, University of Chicago, IL, USA

Trial

Phase 2, PACIFIC-6

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:37

No impact of grade ≥2 pneumonitis on patient-reported outcomes in PACIFIC

Presented By

Prof. Rina Hui, University of Sydney, Australia

Trial

Phase 3, PACIFIC

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:37

Immunotherapy delays deterioration in health-related quality of life in metastatic NSCLC

Presented By

Dr Edward Garon, David Geffen School of Medicine at UCLA, CA, USA

Trial

Phase 3, POSEIDON

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:36

Characteristics of long-term survivors in the CASPIAN trial

Presented By

Dr Niels Reinmuth, Asklepios Lung Clinic, Germany

Trial

Phase 3, CASPIAN

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:34

Outcomes of real-world CANTABRICO trial match results from CASPIAN

Presented By

Dr Dolores Isla, Hospital Clinico Universitario Lozano Blesa, Spain

Trial

CANTABRICO

Conference

ELCC 2022

Type

Peer-reviewed article

25 May 2022 12:33

No benefit of olaparib in previously untreated, platinum-ineligible, metastatic urothelial carcinoma

Presented By

Dr Jonathan Rosenberg, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 2, BAYOU

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:19

Adding lenvatinib to pembrolizumab does not improve survival in advanced urothelial carcinoma

Presented By

Dr Yohann Loriot, Institut Gustave Roussy, France

Trial

Phase 3, LEAP-011

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:18

First-line avelumab shows clinical activity in advanced urothelial carcinoma

Presented By

Dr Roberto Iacovelli, Catholic University of Rome, Italy

Trial

Phase 2, ARIES

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:17

Second-line nivolumab/ipilimumab boost improves ORR in metastatic urothelial carcinoma

Presented By

Prof. Marc-Oliver Grimm, University Hospital Jena, Germany

Trial

Phase 2, TITAN-TCC

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:17

Sacituzumab govitecan effective in platinum-refractory metastatic urothelial cancer

Presented By

Dr Petros Grivas, University of Washington, WA, USA

Trial

Phase 2, TROPHY-U-01

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:16

High-risk early RCC may benefit from neoadjuvant avelumab plus axitinib

Presented By

Dr Axel Bex, Netherlands Cancer Institute, the Netherlands

Trial

Phase 2, NeoAvAx

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:14

DFS benefits with adjuvant pembrolizumab in RCC persist with longer follow-up

Presented By

Dr Toni Choueiri, Dana-Farber Cancer Institute, MA, USA

Trial

Phase 3, KEYNOTE-564

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:14

Biomarkers predict response to immune nivolumab (± ipilimumab) in advanced RCC

Presented By

Dr Marc-Oliver Grimm, University Hospital Jena, Germany

Trial

Phase 2, TITAN-RCC

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:13

Combined nivolumab/axitinib treatment elicits good response in metastatic RCC

Presented By

Dr Matthew Zibelman, Fox Chase Cancer Center, PA, USA

Trial

Phase 1/2

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:13

Nivolumab monotherapy represents an alternative first-line treatment option for treatment-naïve mRCC

Presented By

Dr Michael Atkins, Georgetown Lombardi Comprehensive Cancer Center, DC, USA

Trial

Phase 2, HCRN GU16-260

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:12

Atezolizumab does not improve survival in advanced penile cancer

Presented By

Dr Hielke-Martijn de Vries, Netherlands Cancer Institute, the Netherlands

Trial

Phase 2, PERICLES

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:11

AK104 plus chemotherapy promising first-line option for gastric cancer

Presented By

Dr Jiafu Ji, Beijing Cancer Hospital, China

Trial

Phase 1/2, AK104-201

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 11:19

Nivolumab in gastric cancer: Efficacy update and the role of gut microbiome

Presented By

Dr Kohei Shitara, National Cancer Center Hospital East, Japan; Dr Yu Sunakawa, St. Marianna University School of Medicine, Japan

Trial

Phase 3, CheckMate 649, DELIVER

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 11:11

Updates on pembrolizumab for oesophageal and gastric cancer

Presented By

Dr Jean-Philippe Metges, CHU Brest, France; Dr Zev Wainberg, University College Los Angeles, CA, USA

Trial

Phase 3, KEYNOTE-590, KEYNOTE-062

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 11:08

NIPICOL: New data on optimal ICI treatment duration in MSI/dMMR mCRC

Presented By

Dr Romain Cohen, Sorbonne University, France

Trial

Phase 2, NIPICOL

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 10:30

Dostarlimab may offer an alternative for dMMR rectal cancer

Presented By

Dr Melissa Lumish, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 2

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 10:28

Nivolumab plus standard-of-care does not meet primary endpoint for mCRC

Presented By

Dr Heinz-Josef Lenz, USC Norris Comprehensive Cancer Center, CA, USA

Trial

Phase 3, CheckMate 9X8

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 10:21

Pembrolizumab safe and efficacious in advanced hepatocellular carcinoma

Presented By

Prof. Shukui Qin, Nanjing University of Chinese Medicine, China

Trial

Phase 3, KEYNOTE-394

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 10:11

TOPAZ-1: Adding durvalumab to chemotherapy effective in advanced biliary tract cancer

Presented By

Dr Do-Youn Oh, Seoul National University College of Medicine, South Korea

Trial

Phase 3, TOPAZ-1

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 10:09

HIMALAYA: Durvalumab ± tremelimumab new first-line option for unresectable HCC

Presented By

Prof. Ghassan Abou-Alfa, Memorial Sloan Kettering Center, NY, USA

Trial

Phase 3, HIMALAYA

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 10:05

Double-positive results for triple-negative metastatic breast cancer

Presented By

Prof. Hope Rugo, University of California, San Francisco, USA

Trial

Phase 3, KEYNOTE-355

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:48

Immune chemo-sensitisation looks promising in microsatellite-stable mCRC

Presented By

Dr Filippo Pietrantonio, Istituto Nazionale dei Tumori di Milano, Italy & Dr Chiara Cremolini, Azienda Ospedaliero-Universitaria Pisana, Italy

Trial

Phase 2, MAYA & AtezoTRIBE

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:42

Consistent benefit of anti-PD-1 therapy for oesophageal and gastric cancer

Presented By

Dr Yelena Janjigian, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 3, CheckMate649

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:41

ctDNA highly predictive in HER2-positive, advanced gastric or gastro-oesophageal junction cancer

Presented By

Dr Alexander Stein, University Cancer Center Hamburg, Germany

Trial

Phase 2, INTEGA

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:39

Nivolumab/ipilimumab continues to provide survival benefit in unresectable MPM

Presented By

Prof. Solange Peters, Lausanne University Hospital, Switzerland

Trial

Phase 3, CheckMate743

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:36

Adjuvant atezolizumab lowers relapse rate in resected NSCLC

Presented By

Dr Enriqueta Felip, Vall d’Hebron Institute of Oncology, Spain

Trial

Phase 3, Impower010

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:35

Three-year OS follow-up from CASPIAN trial

Presented By

Dr Luis Paz-Ares, Hospital Universitario 12 de Octubre, Spain

Trial

Phase 3, CASPIAN

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:32

TCR clonality predicts pembrolizumab response in NSCLC

Presented By

Dr Afef Abed, Edith Cowan University, Australia

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:31

Adjuvant immunotherapy reduces risk of disease recurrence in stage II melanoma

Presented By

Dr Jason Luke, UPMC Hillman Cancer Center, PA, USA

Trial

Phase 3, KEYNOTE-716

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:30

IFN-γ signature predicts response to immunotherapy

Presented By

Prof. Christian Blank, Netherlands Cancer Institute, the Netherlands

Trial

Phase 1, DONIMI

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:30

Updated results of SECOMBIT trial

Presented By

Prof. Paolo Ascierto, Istituto Nazionale Tumori "Fondazione Pascale", Italy

Trial

Phase 2, SECOMBIT

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:30

Combining T-VEC and pembrolizumab does not significantly improve survival in advanced, unresectable melanoma

Presented By

Dr Helen Gogas, National and Kapodistrian University of Athens, Greece

Trial

Phase 3, MASTERKEY-265

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:30

Durable intracranial responses with nivolumab/ipilimumab

Presented By

Dr Kim Margolin, City of Hope, CA, USA

Trial

Phase 2, CheckMate204

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:29

Modified ipilimumab schedule reduces risk of grade 3/4 adverse events

Presented By

Dr Naveen Vasudev, St James University Hospital, UK

Trial

Phase 2, PRISM

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:26

Optimal neoadjuvant dose ipilimumab/nivolumab in stage III urothelial cancer

Presented By

Dr Jeroen van Dorp, Netherlands Cancer Institute, the Netherlands

Trial

Phase 1, NABUCCO

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:26

Pembrolizumab prolongs survival in persistent, recurrent, or metastatic cervical cancer

Presented By

Prof. Nicoletta Colombo, Istituto Europeo di Oncologia, Italy

Trial

Phase 3, KEYNOTE-826

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:23

Pembrolizumab has durable effect in previously treated MSI-H/dMMR advanced endometrial cancer

Presented By

Prof. David O’Malley, Ohio State University, USA

Trial

Phase 2, KEYNOTE-158

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:23

Low numbers of M2 macrophages in tumour microenvironment associated with superior response to immunotherapy in Hodgkin lymphoma

Presented By

Dr Liudmila Fedorova, Pavlov University, Russia

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:18

Neutrophils negatively correlate with response to anti-PD-1 monotherapy in dMMR tumours

Presented By

Dr Laetitia Nebot-Bral, Institute Gustave Roussy, France

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:09

Trial explores potential benefit of adding atezolizumab to usual care for mesothelioma

Presented By

Prof. Anne Tsao, MD Anderson Cancer Center, TX, USA

Conference

WCLC 2021

Type

News article

21 September 2021 13:23

Immune checkpoint inhibitors in patients with pre-existing psoriasis

Conference

WPPAC 2021

Type

Peer-reviewed article

17 September 2021 13:35

Neoadjuvant nivolumab plus chemotherapy improves surgical outcomes in NSCLC

Presented By

Dr Jonathan Spicer, McGill University, Canada

Trial

Phase 3, CheckMate 816

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 23:59

Pembrolizumab benefits survival in MSI-H/dMMR metastastic colorectal cancer

Presented By

Prof. Thierry André, Sorbonne University, France

Trial

Phase 3, KEYNOTE 177

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 23:32

Novel dual checkpoint blockade improves progression-free survival in melanoma

Presented By

Dr Evan Lipson, Johns Hopkins University, MD, USA

Trial

Phase 3, RELATIVITY-047

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 22:14

Immune-related adverse events are associated with efficacy of atezolizumab in patients with advanced NSCLC

Presented By

Dr Mark Socinski, AdventHealth Cancer Institute, FL, USA

Trial

Phase 3, IMpower130, IMpower132, IMpower150

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 22:02

Sustained efficacy of nivolumab/ipilimumab plus 2 cycles of chemotherapy in NSCLC

Presented By

Prof. Martin Reck, Lung Clinic Grosshansdorf, Germany

Trial

Phase 3, CheckMate 9LA

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 22:00

Post-nephrectomy pembrolizumab improves disease-free survival

Presented By

Dr Toni Choueiri , Dana-Farber Cancer Institute, MA, USA

Trial

Phase 3, KEYNOTE 564

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 21:23

Benefit of both I-O/chemo combo and I-O/I-O combo over chemotherapy alone in oesophageal squamous cell cancer

Presented By

Dr Ian Chau, Royal Marsden Hospital, UK

Trial

Phase 3, CheckMate 648

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 20:12

Benefit of I-O/chemo combo over chemotherapy alone in advanced GC/GEJC/EAC

Presented By

Prof. Markus Moehler, Mainz University Clinic, Germany

Trial

Phase 3, CheckMate 649

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 19:15

Promising efficacy and safety of feladilimab in recurrent/metastatic urothelial carcinoma

Presented By

Dr Arjun Balar , Perlmutter Cancer Center, NY, USA

Trial

Phase 1, INDUCE-1

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 12:30

Neoadjuvant therapy with nivolumab plus relatlimab is safe and effective in patients with stage III melanoma

Presented By

Dr Rodabe Amaria , MD Anderson Cancer Center, TX, USA

Trial

Phase 2

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 12:16

Durvalumab after chemoradiation proven safe in elderly NSCLC patients

Presented By

Dr. Adrian Sacher, Princess Margaret Cancer Centre, Toronto, ON, Canada

Journal

Physician's Weekly

Conference

ASCO 2021

6 August 2021 12:21

Doubling overall survival in US veterans with stage 3 non-small cell lung cancer

Presented By

Dr. Nithya Ramnath, University of Michigan

Trial

PACIFIC

Journal

Physician's Weekly

Conference

ASCO 2021

6 August 2021 12:17

5-year PACIFIC data hold strong in NSCLC

Presented By

Dr. Camille Hertzka, AstraZeneca

Trial

Phase 3, PACIFIC

Journal

Physician's Weekly

Conference

ASCO 2021

6 August 2021 12:05

Early-Stage NSCLC: Promising Data for Neoadjuvant Durvalumab With Stereotactic Body Radiotherapy

Presented By

Dr Nassar Altorki, New York Presbyterian-Weill Cornell Medical Center, New York, USA

Journal

Physician's Weekly

Conference

ASCO 2021

6 August 2021 11:29

Novel imaging biomarkers predict benefit in stage 3 NSCLC treated with chemoradiation and durvalumab

Presented By

Dr. Khalid Jazieh, Cleveland Clinic, Ohio, USA

Journal

Physician's Weekly

Conference

ASCO 2021

6 August 2021 11:24

T-DXd Combinations in HER2-positive Metastatic Breast Cancer

Presented By

Dr Fabrice André, Institut Gustave Roussy, Paris, France

Trial

Phase 2, DESTINY-Breast07

Journal

Physician's Weekly

Conference

ASCO 2021

6 August 2021 10:55

Immuno-oncology agents are effective in treating classic Hodgkin’s lymphoma

Presented By

Dr Marc André, Centre Hospitalier Universitaire UCL Namur, Belgium

Trial

CheckMate 205; KEYNOTE-087

Conference

EHA 2021

Type

Peer-reviewed article

5 August 2021 12:26

CLEAR trial: promising new combination to treat RCC

Presented By

Dr Alain Ravaud, Centre Hospitalier Universitaire de Bordeaux, France

Trial

Phase 3, CLEAR

Journal

Physician’s Weekly

Conference

ASCO GU 2021

15 April 2021 16:19

Chemoimmunotherapy is effective in a subset of small cell lung cancer patients

Presented By

Prof. Taofeek Owonikoko, Emory University School of Medicine

Trial

KEYNOTE-604, ECOG-ACRIN EA5161

Journal

Physician’s Weekly

Conference

ASCO20 Virtual Meeting

15 April 2021 16:03

SABCS 2020: Adding nivolumab to trastuzumab deruxtecan is well tolerated

Presented By

Erika Hamilton, Sarah Cannon Research Institute at Tennessee Oncology in Nashville, TN

Trial

DESTINY-Breast01

Conference

SABCS 2020

13 April 2021 17:11

ES-SCLC: CASPIAN trial perspectives from Prof. Jonathan Goldman

Presented By

Prof. Jonathan Goldman, Prof. Luis Paz-Ares

Trial

Phase 3, CASPIAN

Journal

Physician Weekly

Conference

ASCO Annual Meeting 2020

13 April 2021 16:27

First-line immune checkpoint inhibition in metastatic NSCLC

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 15:00

PD-L1 density, a new predictive biomarker in NSCLC

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 14:59

Immuno-combination therapy in metastatic melanoma

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 14:52

Treatment of newly diagnosed ovarian cancer

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 14:39

Bispecific antibodies targeting PD-1 and CTLA-4: new kids on the block(ade)

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 12:45

PD-(L)1, LAG-3, and TIM blockade

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 12:43

REGOMUNE: a phase 2 study combining regorafenib and avelumab

Expert

Dr Sophie Cousin, Institut Bergonié, France

Trial

Phase 1/2, REGOMUNE

Conference

ASCO 2020

Type

Peer-reviewed article

17 September 2020 14:52

Urothelial cancer: avelumab works as maintenance therapy

Expert

Prof. Thomas Powles, Barts Cancer Institute, UK

Trial

Phase 3, JAVELIN Bladder 100

Conference

ASCO 2020

17 September 2020 14:30

Primary analysis from IMvigor010, adjuvant atezolizumab in high risk muscle-invasive urothelial carcinoma

Expert

Dr Maya H.A. Hussain, Northwestern University in Chicago, IL, USA

Trial

Phase 3, IMvigor010

Conference

ASCO 2020

Type

Peer-reviewed article

17 September 2020 13:57

Promising first immunotherapy trial in placental trophoblastic tumours

Expert

Prof. Benoit You, Lyon University Hospital, France

Trial

Phase 2, TROPHIMMUN

Conference

ASCO 2020

9 September 2020 14:17

ES-SCLC: pembrolizumab KEYNOTE-604 data

Presented By

Dr Charles M. Rudin, Memorial Sloan Kettering Cancer Center, USA

Trial

Phase 3, KEYNOTE-604

Conference

ASCO 2020

Type

Peer-reviewed article

8 September 2020 13:20

Tiragolumab and atezolizumab: ORR in NSCLC

Presented By

Dr Delvys Rodriguez-Abreu, NYU Perlmutter Cancer Center, USA

Trial

Phase 2, CITYSCAPE

Conference

ASCO 2020

Type

Peer-reviewed article

8 September 2020 13:15

Combination pembrolizumab/chemo improves PFS in metastatic TNBC

Presented By

Dr Javier Cortés & Catherine M. Kelly

Trial

KEYNOTE-355

Conference

ASCO 2020

Type

Peer-reviewed article

8 September 2020 09:32

Pembrolizumab plus low-dose ipilimumab well tolerated after progression on PD1 antibody therapy

Principal Investigator

Dr Daniel Olson, The University of Chicago Comprehensive Cancer Center, IL, USA

Trial

Phase 2

Conference

ASCO 2020

Type

Peer-reviewed article

28 August 2020 15:05

Toripalimab plus axitinib effective in metastatic mucosal melanoma

Presented By

Dr Xinan Sheng, Peking University Cancer Hospital and Institute, China

Trial

Phase 1

Conference

ASCO 2020

Type

Peer-reviewed article

28 August 2020 14:13

No higher pathologic complete response with atezolizumab added to chemotherapy

Trial

IMpassion130

Conference

SABCS 2019

Type

Peer-reviewed article

13 February 2020 23:54

Neoadjuvant + adjuvant pembrolizumab improves pCR in triple-negative breast cancer with lymph node involvement

Trial

KEYNOTE-173, Phase 1b ; I-SPY 2, Phase 2 ; KEYNOTE-522, Phase 3

Conference

SABCS 2019

Type

Peer-reviewed article

13 February 2020 22:56